NCT05240651

Brief Summary

This is a prospective cohort study for 50 patients admitted to the cardiac care unit requiring clinically-indicated diuretic therapy for congestive heart failure. The purpose of this study is to assess the role of non-invasive cardiac output monitoring (NICOM) with the Starling Fluid Management System (Baxter Medical, Deerfield, IL) in determining volume status in patients with acute decompensated heart failure requiring intravenous diuretic therapy.

Trial Health

53
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial recruitment is currently suspended
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
13mo left

Started Aug 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress78%
Aug 2022Jul 2027

First Submitted

Initial submission to the registry

February 13, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 15, 2022

Completed
7 months until next milestone

Study Start

First participant enrolled

August 30, 2022

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

May 8, 2026

Status Verified

May 1, 2026

Enrollment Period

4.8 years

First QC Date

February 13, 2022

Last Update Submit

May 5, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percent Change in Stroke Volume Index (SVI) after passive leg raise (PLR)

    The Startling System non-invasive cardiac output monitoring (NICOM) device will use a proprietary algorithm to determine SVI. A passive leg raise (PLR) is then performed to increase preload and then the Starling System takes a second set of measurements to determine the parameters above as well as the change in stroke volume index.

    Baseline, At Discharge (up to 1 week)

Secondary Outcomes (10)

  • Change in Stroke Volume Index (SVI) before passive leg raise (PLR)

    Baseline, At Discharge (up to 1 week)

  • Change in Stroke Volume Index (SVI) after passive leg raise (PLR)

    Baseline, At Discharge (up to 1 week)

  • Change in estimated Cardiac Output (CO) before passive leg raise (PLR)

    Baseline, At Discharge (up to 1 week)

  • Change in estimated Cardiac Output (CO) after passive leg raise (PLR)

    Baseline, At Discharge (up to 1 week)

  • Change in estimated Cardiac Index (CI) before passive leg raise (PLR)

    Baseline, At Discharge (up to 1 week)

  • +5 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

* Adults age \> 18 * Decompensated heart failure requiring clinically-indicated intravenous (IV) diuresis * Admission to the cardiac care unit (CCU) or the step down unit (SDU) * Ability to perform a passive leg raise (PLR)

You may qualify if:

  • Diagnosis of congestive acute decompensated heart failure (preserved or reduced ejection fraction) requiring clinically indicated IV diuresis
  • Admission to coronary/cardiac intensive care unit or cardiac step down unit
  • Able to provide written informed consent
  • Anticipated need for IV diuretics \> 24 hrs

You may not qualify if:

  • Prisoner, pregnancy or post-partum stage, or age \< 18 years
  • Known allergy to sensory material or gel
  • End stage renal disease or need for CRRT
  • Inability or contraindication to do a passive leg raise with both extremities (i.e., balloon pump, impella, spinal injury, amputation)
  • Other situation that might increase subject risk, interfere with study procedures, or confound study findings based on the opinion of the clinician/investigator
  • Inability to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

Location

Study Officials

  • Carlos Alviar, MD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 13, 2022

First Posted

February 15, 2022

Study Start

August 30, 2022

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

May 8, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access Criteria
The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to carlos.alviar@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

Locations